{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:56:50Z","timestamp":1792565810925,"version":"4.5.0"},"reference-count":189,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001412","name":"CSIR","doi-asserted-by":"publisher","award":["38(1434)\/17\/EMR-II"],"award-info":[{"award-number":["38(1434)\/17\/EMR-II"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ejmech.2019.05.027","type":"journal-article","created":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T18:52:38Z","timestamp":1557600758000},"page":"268-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":318,"special_numbering":"C","title":["Natural products as multidrug resistance modulators in cancer"],"prefix":"10.1016","volume":"176","author":[{"given":"Amit","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Jaitak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.05.027_bib1","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.addr.2013.09.019","article-title":"Nanomedicine therapeutic approaches to overcome cancer drug resistance","volume":"65","author":"Markman","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2019.05.027_bib2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancer in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2019.05.027_bib3","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.biotechadv.2013.06.004","article-title":"Different strategies to overcome multidrug resistance in cancer","volume":"31","author":"Saraswathy","year":"2013","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ejmech.2019.05.027_bib4","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.addr.2013.09.017","article-title":"Nanotechnology approaches for personalized treatment of multidrug resistant cancer","volume":"65","author":"Minko","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2019.05.027_bib5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3109\/07388551.2015.1015957","article-title":"Molecular mechanisms of drug resistance and its reversal in cancer","volume":"36","author":"Kartal-Yandim","year":"2016","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.05.027_bib7","series-title":"Multi-Drug Resistance in Cancer","first-page":"47","article-title":"Mechanisms of multidrug resistance in cancer","author":"Gillet","year":"2010"},{"key":"10.1016\/j.ejmech.2019.05.027_bib8","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tr\u00e9dan","year":"2007","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2019.05.027_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumor heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/2159-8290.CD-15-0748","article-title":"Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET amplified esophagogastric cancer","volume":"5","author":"Kwak","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2019.05.027_bib11","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.18632\/oncotarget.3076","article-title":"Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2019.05.027_bib12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.18632\/oncotarget.2732","article-title":"Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance","volume":"6","author":"Zhitomirsky","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2019.05.027_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","article-title":"Lysosomes as mediators of drug resistance in cancer","volume":"24","author":"Zhitomirsky","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2019.05.027_bib14","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/35037747","article-title":"From bench to clinic with apoptosis-based therapeutic agents","volume":"407","author":"Nicholson","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.05.027_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0009-2797(89)90117-8","article-title":"Free radicals in anticancer drug pharmacology","volume":"69","author":"Sinha","year":"1989","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2019.05.027_bib16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0891-5849(90)90155-C","article-title":"Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors","volume":"8","author":"Sinha","year":"1990","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2019.05.027_bib17","first-page":"599","article-title":"Vitamin free radicals and their anticancer action","volume":"vol 23","author":"Getoff","year":"2009"},{"key":"10.1016\/j.ejmech.2019.05.027_bib18","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2165\/11592590-000000000-00000","article-title":"Cellular redox pathways as a therapeutic target in the treatment of cancer","volume":"71","author":"Montero","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2019.05.027_bib19","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00280-018-3584-x","article-title":"IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1)","volume":"81","author":"Du","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.11.013","article-title":"Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy","volume":"149","author":"Silva","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2019.05.027_bib21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/molecules22040600","article-title":"Cellular models and in\u00a0Vitro assays for the screening of modulators of P-gp, MRP1 and BCRP","volume":"22","author":"Gameiro","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2019.05.027_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00424-006-0126-x","article-title":"Structure and function of ABC transporters: the ATP switch provides flexible control","volume":"453","author":"Linton","year":"2007","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.ejmech.2019.05.027_bib23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/14728222.2017.1310841","article-title":"The therapeutic potential of targeting ABC transporters to combat multi-drug resistance","volume":"21","author":"Bugde","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2019.05.027_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1152\/physiol.00046.2006","article-title":"Structure and function of ABC transporters","volume":"22","author":"Linton","year":"2007","journal-title":"Physiology"},{"key":"10.1016\/j.ejmech.2019.05.027_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2019.05.027_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006942","article-title":"Genetic variation in the proximal promoter of ABC and SLC Superfamilies: liver and kidney specific expression and promoter activity predict variation","volume":"4","author":"Hesselson","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.05.027_bib27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pharmtox-010611-134529","article-title":"Drug transporters in drug efficacy and toxicity","volume":"52","author":"DeGorter","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.bcp.2005.06.018","article-title":"Expression of the drug transporters MDR1\/ABCB1, MRP1\/ABCC1, MRP2\/ABCC2, BCRP\/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver","volume":"70","author":"Albermann","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.ki.5002645","article-title":"The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane","volume":"73","author":"Huls","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2019.05.027_bib30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.12703\/P7-14","article-title":"Structure and mechanism of ABC transporters","volume":"7","author":"Wilkens","year":"2015","journal-title":"F1000Prime Rep."},{"key":"10.1016\/j.ejmech.2019.05.027_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A\u00a0surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ejmech.2019.05.027_bib32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1126\/science.aar7389","article-title":"Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation","volume":"359","author":"Kim","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2019.05.027_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1028-4559(09)60296-5","article-title":"Mechanisms of chemotherapeutic drug resistance in cancer therapy\u2014a quick review","volume":"48","author":"Liu","year":"2009","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bcp.2014.10.009","article-title":"Identification of new P-glycoprotein inhibitors derived from cardiotonic steroids","volume":"93","author":"Zeino","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib35","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1360704","article-title":"Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line","volume":"258","author":"Cole","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2019.05.027_bib36","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cell.2017.01.041","article-title":"Structural basis of substrate recognition by the multidrug resistance protein MRP1","volume":"168","author":"Johnson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2019.05.027_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","article-title":"Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense","volume":"204","author":"Leslie","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-pharmtox-011613-135959","article-title":"Targeting Multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future","volume":"54","author":"Cole","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib39","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cell.2017.01.041","article-title":"Structural basis of substrate recognition by the multidrug resistance protein MRP1","volume":"168","author":"Johnson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2019.05.027_bib40","doi-asserted-by":"crossref","first-page":"15091","DOI":"10.1074\/jbc.271.25.15091","article-title":"cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cmrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats","volume":"271","author":"B\u00fcchler","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib41","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1111\/j.1742-4658.2011.08235.x","article-title":"Multidrug resistance proteins (MRPs\/ABCCs) in cancer chemotherapy and genetic diseases","volume":"278","author":"Chen","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2019.05.027_bib42","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00424-006-0109-y","article-title":"The apical conjugate efflux pump ABCC2 (MRP2)","volume":"453","author":"Nies","year":"2007","journal-title":"Pflueg. Arch. Eur. J. Physiol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/17425255.2015.981152","article-title":"New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition","volume":"11","author":"van der Schoor","year":"2015","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3109\/03602530903491741","article-title":"ABCC2\/Abcc2: a multispecific transporter with dominant excretory functions","volume":"42","author":"Jemnitz","year":"2010","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejmech.2019.05.027_bib45","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1208\/s12248-015-9757-1","article-title":"Multidrug resistance proteins (MRPs) and cancer therapy","volume":"17","author":"Zhang","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.ejmech.2019.05.027_bib46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/08880018.2013.870625","article-title":"Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia","volume":"31","author":"Sharifi","year":"2014","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.1365-2559.2002.01403.x","article-title":"Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays","volume":"41","author":"Sandusky","year":"2002","journal-title":"Histopathology"},{"key":"10.1016\/j.ejmech.2019.05.027_bib48","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1080\/00498254.2016.1262976","article-title":"ABCC2 (1249G\u2009>\u2009A) polymorphism implicates altered transport activity for sorafenib","volume":"47","author":"Wei","year":"2017","journal-title":"Xenobiotica"},{"issue":"26","key":"10.1016\/j.ejmech.2019.05.027_bib49","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A\u00a0multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2019.05.027_bib50","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1152\/physrev.00037.2005","article-title":"Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system","volume":"86","author":"Sarkadi","year":"2006","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2019.05.027_bib51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41594-018-0049-1","article-title":"Structural basis of small-molecule inhibition of human multidrug transporter ABCG2","volume":"25","author":"Jackson","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib52","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00204-014-1224-8","article-title":"Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics","volume":"88","author":"Jani","year":"2014","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1043-6618(03)00158-0","article-title":"P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement","volume":"48","author":"Varma","year":"2003","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2019.05.027_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2015.10.010","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade","volume":"370","author":"Chen","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2019.05.027_bib56","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2174\/092986712800167392","article-title":"Three decades of P-gp inhibitors: skimming through several generations and scaffolds","volume":"19","author":"Palmeira","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib57","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1995.13.8.1985","article-title":"Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy","volume":"13","author":"Wilson","year":"1995","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib58","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1200\/JCO.2000.18.9.1837","article-title":"P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in\u00a0vivo in patients with P-glycoprotein\u2013positive acute myeloid leukemia","volume":"18","author":"Tidefelt","year":"2000","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib59","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/1078-0432.CCR-0914-3","article-title":"VX-710 (Biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein","volume":"10","author":"Minderman","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib60","first-page":"18","article-title":"Defeating drug resistance in cancer","volume":"6","author":"Gottesman","year":"2009","journal-title":"Discov. Med."},{"key":"10.1016\/j.ejmech.2019.05.027_bib61","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/138945006777709593","article-title":"Pharmacological strategies for overcoming multidrug resistance","volume":"7","author":"Nobili","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2019.05.027_bib62","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nucmedbio.2009.03.004","article-title":"Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats","volume":"36","author":"Luurtsema","year":"2009","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib63","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00280-003-0720-y","article-title":"The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice","volume":"53","author":"Kemper","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib64","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/jcem-73-1-18","article-title":"Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1\/P-glycoprotein) which is also expressed by adrenocortical carcinomas","volume":"73","author":"Bates","year":"1991","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2019.05.027_bib65","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14737140.7.4.447","article-title":"Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor","volume":"7","author":"Fox","year":"2007","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2019.05.027_bib66","first-page":"4595","article-title":"In\u00a0vitro and in\u00a0vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative","volume":"53","author":"Hyafil","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib67","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0022-3565(24)34974-2","article-title":"Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities","volume":"290","author":"Dantzig","year":"1999","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2019.05.027_bib68","first-page":"749","article-title":"In\u00a0vitro and in\u00a0vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576","volume":"61","author":"Mistry","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib69","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2002.12.116","article-title":"Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918","volume":"20","author":"Kruijtzer","year":"2002","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib70","first-page":"4171","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979","volume":"56","author":"Dantzig","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib71","series-title":"Development of Inhibitors of ATP-Binding Cassette Drug Transporters: Present Status and Challenges","author":"Shukla","year":"2008"},{"key":"10.1016\/j.ejmech.2019.05.027_bib72","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/cncr.21227","article-title":"Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma","volume":"104","author":"Lajos","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2019.05.027_bib73","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.addr.2008.10.004","article-title":"QSAR analysis and molecular modeling of ABCG2-specific inhibitors","volume":"61","author":"Nicolle","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2019.05.027_bib74","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.apsb.2018.04.007","article-title":"Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies","volume":"8","author":"Bumbaca","year":"2018","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.ejmech.2019.05.027_bib75","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/107327480301000207","article-title":"Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein","volume":"10","author":"Thomas","year":"2003","journal-title":"Cancer Control"},{"key":"10.1016\/j.ejmech.2019.05.027_bib76","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1016\/j.bmc.2018.08.021","article-title":"Discovery of a non-toxic [1,2,4]triazolo[1,5-a]pyrimidin-7-one (WS-10) that modulates ABCB1-mediated multidrug resistance (MDR)","volume":"26","author":"Chang","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jare.2014.11.008","article-title":"P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review","volume":"6","author":"Abdallah","year":"2015","journal-title":"J.\u00a0Adv. Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib78","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1517\/13543784.2012.679339","article-title":"Investigational ABC transporter inhibitors","volume":"21","author":"Falasca","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejmech.2019.05.027_bib79","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bcp.2016.01.014","article-title":"Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: functional and molecular docking analyses","volume":"104","author":"Kadioglu","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib80","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3109\/14756366.2016.1149476","article-title":"Advances in plant-based inhibitors of P-glycoprotein","volume":"31","author":"Yu","year":"2016","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/md13042010","article-title":"Marine natural products as breast cancer resistance protein inhibitors","volume":"13","author":"Cherigo","year":"2015","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2019.05.027_bib82","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1016\/j.ejmech.2011.07.057","article-title":"Natural products: an evolving role in future drug discovery","volume":"46","author":"Mishra","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib83","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1749-8546-5-26","article-title":"Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines","volume":"5","author":"Chai","year":"2010","journal-title":"Chin. Med."},{"key":"10.1016\/j.ejmech.2019.05.027_bib84","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1021\/cr900019j","article-title":"Impact of natural products on developing new anti-cancer agents","volume":"109","author":"Cragg","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.05.027_bib85","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1017\/jns.2016.41","article-title":"Flavonoids: an overview","volume":"5","author":"Panche","year":"2016","journal-title":"J.\u00a0Nutr. Sci."},{"key":"10.1016\/j.ejmech.2019.05.027_bib86","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0163-7258(02)00298-X","article-title":"The biochemistry and medical significance of the flavonoids","volume":"96","author":"Havsteen","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2019.05.027_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2012.00222","article-title":"Flavonoids: biosynthesis, biological functions, and biotechnological applications","volume":"3","author":"Falcone Ferreyra","year":"2012","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.ejmech.2019.05.027_bib88","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/med.10015","article-title":"Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance","volume":"22","author":"Boumendjel","year":"2002","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2019.05.027_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00044-013-0612-6","article-title":"Impact of ABC transporters, glutathione conjugates in MDR and their modulation by flavonoids: an overview","volume":"23","author":"Gupta","year":"2014","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib90","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.bmc.2010.12.043","article-title":"Structure\u2013activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP)","volume":"19","author":"Pick","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib91","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1021\/cr4006236","article-title":"Targeting the achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance","volume":"114","author":"Szak\u00e1cs","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.05.027_bib92","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/abbi.1999.1550","article-title":"Differential effects of flavonoid compounds on tumor promoter-induced activation of the human CYP1A2 enhancer","volume":"373","author":"Shih","year":"2000","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2019.05.027_bib93","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0006-2952(96)00826-X","article-title":"Effect of quercetin on hoechst 33342 transport by purified and reconstituted P-glycoprotein","volume":"53","author":"Shapiro","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib94","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1179\/joc.2005.17.1.86","article-title":"Inhibition of P-glycoprotein function and expression by kaempferol and quercetin","volume":"17","author":"Limtrakul","year":"2005","journal-title":"J.\u00a0Chemother."},{"key":"10.1016\/j.ejmech.2019.05.027_bib95","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1016\/j.fct.2012.06.035","article-title":"In\u00a0vitro effect of quercetin on human gastric carcinoma: targeting cancer cells death and MDR","volume":"50","author":"Borska","year":"2012","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib96","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3892\/mmr.2014.2734","article-title":"Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of mitogen-activated protein kinase\/extracellular signal-regulated kinase\/c-Jun N-terminal kinase signaling in multidrug-resistant leukemia K562 cells","volume":"11","author":"Chen","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2019.05.027_bib97","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/01635581.2015.965334","article-title":"Quercetin inhibits proliferation and drug resistance in KB\/VCR oral cancer cells and enhances its sensitivity to vincristine","volume":"67","author":"Yuan","year":"2015","journal-title":"Nutr. Canc."},{"key":"10.1016\/j.ejmech.2019.05.027_bib98","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.bmc.2016.12.034","article-title":"Quercetin-glutamic acid conjugate with a non-hydrolysable linker; a novel scaffold for multidrug resistance reversal agents through inhibition of P-glycoprotein","volume":"25","author":"Kim","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib99","doi-asserted-by":"crossref","first-page":"7216","DOI":"10.1021\/jm500290c","article-title":"Water-soluble and cleavable quercetin\u2013amino acid conjugates as safe modulators for P-glycoprotein-based multidrug resistance","volume":"57","author":"Kim","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.phymed.2018.03.040","article-title":"Reversal effect of quercetin on multidrug resistance via FZD7\/\u03b2-catenin pathway in hepatocellular carcinoma cells","volume":"43","author":"Chen","year":"2018","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2019.05.027_bib101","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jep.2012.10.012","article-title":"Effects of Zuccagnia punctata extracts and their flavonoids on the function and expression of ABCB1\/P-glycoprotein multidrug transporter","volume":"144","author":"Chieli","year":"2012","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib102","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1021\/jf104786t","article-title":"Quercetin and rutin reduced the bioavailability of cyclosporine from neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4","volume":"59","author":"Yu","year":"2011","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib103","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1155\/2013\/382350","article-title":"Absorption and metabolism characteristics of rutin in Caco-2 cells","volume":"2013","author":"Zhang","year":"2013","journal-title":"Sci. World J."},{"key":"10.1016\/j.ejmech.2019.05.027_bib104","first-page":"379","article-title":"Effects of kaempferol on the mechanisms of drug resistance in the human glioblastoma cell line T98G","volume":"65","author":"Nakatsuma","year":"2010","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejmech.2019.05.027_bib105","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3109\/03639045.2013.819885","article-title":"Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in\u00a0vitro","volume":"40","author":"Surya Sandeep","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejmech.2019.05.027_bib106","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.3892\/mmr.2013.1742","article-title":"Icaritin reverses multidrug resistance of HepG2\/ADR human hepatoma cells via downregulation of MDR1 and P-glycoprotein expression","volume":"8","author":"Sun","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2019.05.027_bib107","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s12272-011-1117-9","article-title":"Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome p450 3A4 and P-glycoprotein inhibition by baicalein","volume":"34","author":"Li","year":"2011","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.ejmech.2019.05.027_bib108","first-page":"20","article-title":"Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells","volume":"16","author":"Wang","year":"2018","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.ejmech.2019.05.027_bib109","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1749-6632.2009.04722.x","article-title":"Inhibition of P-glycoprotein by wogonin is involved with the potentiation of etoposide-induced apoptosis in cancer cells","volume":"1171","author":"Lee","year":"2009","journal-title":"Ann. NY. Acad. Sci."},{"key":"10.1016\/j.ejmech.2019.05.027_bib110","first-page":"197","article-title":"Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA\/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy","volume":"24","author":"Angelini","year":"2010","journal-title":"J.\u00a0Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.ejmech.2019.05.027_bib111","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1021\/np3003468","article-title":"Multidrug resistance reversal and apoptosis induction in human colon cancer cells by some flavonoids present in citrus plants","volume":"75","author":"Wesolowska","year":"2012","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2019.05.027_bib112","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejphar.2008.10.025","article-title":"Effects of chemopreventive citrus phytochemicals on human P-glycoprotein and multidrug resistance protein 1","volume":"600","author":"Nabekura","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib113","first-page":"111","article-title":"Green tea catechins augment the antitumor activity of doxorubicin in an in\u00a0vivo mouse model for chemoresistant liver cancer","volume":"37","author":"Liang","year":"2010","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib114","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.apsb.2018.10.001","article-title":"The epigallocatechin gallate derivative Y6 reverses drug resistance mediated by the ABCB1 transporter both in\u00a0vitro and in\u00a0vivo","volume":"9","author":"Wen","year":"2019","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.ejmech.2019.05.027_bib115","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.phymed.2009.09.004","article-title":"Effects of curcuma spp. on P-glycoprotein function","volume":"17","author":"Ampasavate","year":"2010","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2019.05.027_bib116","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.3390\/molecules15053135","article-title":"Flavonoids from Artemisia annua L. as Antioxidants and their potential synergism with artemisinin against malaria and cancer","volume":"15","author":"Ferreira","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2019.05.027_bib117","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1124\/mol.65.5.1208","article-title":"Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-Mediated transport","volume":"65","author":"Zhang","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib118","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ptr.5447","article-title":"Recent trends in preclinical drug\u2013drug interaction studies of flavonoids\u2009\u2014\u2009Review of case studies, issues and perspectives","volume":"29","author":"Srinivas","year":"2015","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib119","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2174\/1389200216666150206123719","article-title":"Disposition of flavonoids impacts their efficacy and safety","volume":"15","author":"Ma","year":"2014","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib120","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3945\/ajcn.113.065789","article-title":"Intestinal absorption, metabolism, and excretion of (\u2013)-epicatechin in healthy humans assessed by using an intestinal perfusion technique","volume":"98","author":"Actis-Goretta","year":"2013","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ejmech.2019.05.027_bib121","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2174\/187152012803833107","article-title":"Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME","volume":"12","author":"Yang","year":"2012","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib122","first-page":"401","article-title":"Natural alkaloids: basic aspects, biological roles, and future perspectives","volume":"12","author":"Qiu","year":"2014","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.ejmech.2019.05.027_bib123","series-title":"Comprehensive Natural Products II","first-page":"977","article-title":"1.25 - alkaloids","author":"O'Connor","year":"2010"},{"key":"10.1016\/j.ejmech.2019.05.027_bib124","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.foodchem.2012.09.059","article-title":"An isoquinoline alkaloid from the Chinese herbal plant Corydalis yanhusuo W.T. Wang inhibits P-glycoprotein and multidrug resistance-associate protein 1","volume":"136","author":"Lei","year":"2013","journal-title":"Food Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.canlet.2009.06.009","article-title":"Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice","volume":"287","author":"Wu","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2019.05.027_bib126","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00280-003-0742-5","article-title":"Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance","volume":"53","author":"Fu","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib127","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.bcp.2011.08.012","article-title":"H1, a derivative of Tetrandrine, exerts anti-MDR activity by initiating intrinsic apoptosis pathway and inhibiting the activation of Erk1\/2 and Akt1\/2","volume":"82","author":"Wei","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib128","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3892\/or.2012.1999","article-title":"Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein 1","volume":"28","author":"Wang","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2019.05.027_bib129","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1021\/acs.molpharmaceut.7b00381","article-title":"Reduction-sensitive paclitaxel prodrug self-assembled nanoparticles with tetrandrine effectively promote synergistic therapy against drug-sensitive and multidrug-resistant breast cancer","volume":"14","author":"Jiang","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2019.05.027_bib130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/aps.2009.19","article-title":"Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in\u00a0vitro and in\u00a0vivo","volume":"30","author":"Wei","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2019.05.027_bib131","first-page":"461","article-title":"Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7\/DOX) cells","volume":"43","author":"Wang","year":"2008","journal-title":"Yao Xue Xue Bao"},{"key":"10.1016\/j.ejmech.2019.05.027_bib132","first-page":"52","article-title":"Autophagy and multidrug resistance in cancer","volume":"36","author":"Li","year":"2017","journal-title":"Chin. J. Canc."},{"key":"10.1016\/j.ejmech.2019.05.027_bib133","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1021\/acs.jnatprod.6b00597","article-title":"Hernandezine, a bisbenzylisoquinoline alkaloid with selective inhibitory activity against multidrug-resistance-linked ATP-binding cassette drug transporter ABCB1","volume":"79","author":"Hsiao","year":"2016","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2019.05.027_bib134","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1073\/pnas.86.13.5128","article-title":"Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance","volume":"86","author":"Pearce","year":"1989","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2019.05.027_bib135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/1087057105284576","article-title":"A\u00a0High-Throughput cell-based assay for inhibitors of ABCG2 Activity","volume":"11","author":"Henrich","year":"2005","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.ejmech.2019.05.027_bib136","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/np400950h","article-title":"Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts","volume":"77","author":"Condello","year":"2014","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2019.05.027_bib137","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1021\/np50113a007","article-title":"Indole alkaloids from Peschiera laeta that enhance vinblastine-mediated cytotoxicity with multi-drug-resistant cells","volume":"57","author":"You","year":"1994","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2019.05.027_bib138","first-page":"1505","article-title":"Voacamine, a bisindolic alkaloid from Peschiera fuchsiaefolia, enhances the cytotoxic effect of doxorubicin on multidrug-resistant tumor cells","volume":"23","author":"Meschini","year":"2003","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib139","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1021\/np900576b","article-title":"(\u2212)-Eburnamaline, biologically active strychnan and eburnan alkaloids from leuconotis","volume":"72","author":"Gan","year":"2009","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2019.05.027_bib140","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.bmc.2013.12.022","article-title":"Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication","volume":"22","author":"Munagala","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib141","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1349-7006.2002.tb01260.x","article-title":"Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells","volume":"93","author":"Shiraki","year":"2005","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib142","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ptr.2860","article-title":"The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells","volume":"24","author":"Ma","year":"2009","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib143","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/np9001477","article-title":"Tabernines A\u2212C, \u03b2-Carbolines from the leaves of Tabernaemontana elegans","volume":"72","author":"Mansoor","year":"2009","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2019.05.027_bib144","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.phytochem.2014.09.014","article-title":"Corynanthean, eburnan, secoleuconoxine, and pauciflorine alkaloids from Kopsia pauciflora","volume":"108","author":"Gan","year":"2014","journal-title":"Phytochemistry"},{"key":"10.1016\/j.ejmech.2019.05.027_bib145","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.fitote.2011.01.015","article-title":"Alkaloids derived from genus Veratrum and Peganum of Mongolian origin as multidrug resistance inhibitors of cancer cells","volume":"82","author":"Ivanova","year":"2011","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ejmech.2019.05.027_bib146","series-title":"Role of Nutraceuticals in Cancer Chemosensitization","first-page":"259","article-title":"Chapter 13 - role of piperine in chemoresistance","author":"Kumar","year":"2018"},{"key":"10.1016\/j.ejmech.2019.05.027_bib147","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/bdd.1811","article-title":"Repeated dosing of piperine induced gene expression of P-glycoprotein via stimulated pregnane-X-receptor activity and altered pharmacokinetics of diltiazem in rats","volume":"33","author":"Qiang","year":"2012","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.ejmech.2019.05.027_bib148","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.phymed.2007.11.028","article-title":"Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells","volume":"15","author":"Ma","year":"2008","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2019.05.027_bib149","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.phymed.2010.07.014","article-title":"Stemona alkaloids, from traditional Thai medicine, increase chemosensitivity via P-glycoprotein-mediated multidrug resistance","volume":"18","author":"Chanmahasathien","year":"2011","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2019.05.027_bib150","first-page":"2737","article-title":"Antitumor properties of acridone alkaloids on a murine lymphoma cell line","volume":"28","author":"Rethy","year":"2008","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib151","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ptr.2081","article-title":"Modulation of P-glycoprotein activity by acridones and coumarins from Citrus sinensis","volume":"21","author":"Bayet","year":"2007","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib152","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.fct.2011.11.008","article-title":"Anti-proliferative activity and suppression of P-glycoprotein by (\u2212)-antofine, a natural phenanthroindolizidine alkaloid, in paclitaxel-resistant human lung cancer cells","volume":"50","author":"Kim","year":"2012","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib153","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.yexcr.2012.12.017","article-title":"The elimination of P-glycoprotein over-expressing cancer cells by antimicrobial cationic peptide NK-2: the unique way of multi-drug resistance modulation","volume":"319","author":"Bankovi\u0107","year":"2013","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib154","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.canlet.2008.04.033","article-title":"Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402\/5-FU","volume":"269","author":"Shi","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2019.05.027_bib155","article-title":"Clitocine Reversal of P-glycoprotein associated multi-drug resistance through down-regulation of transcription factor NF-\u03baB in R-HepG2 cell line","volume":"7","author":"Sun","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.05.027_bib156","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054044","article-title":"Purine Nucleoside Analog - sulfinosine modulates diverse mechanisms of cancer progression in multi-drug resistant cancer cell lines","volume":"8","author":"Da\u010devi\u0107","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.05.027_bib157","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083467","article-title":"Olomoucine II and Roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of Daunorubicin in\u00a0Vitro","volume":"8","author":"Cihalova","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.05.027_bib158","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1021\/np400034d","article-title":"Structure\u2013activity relationship analysis of bufadienolide-induced in\u00a0vitro growth inhibitory effects on mouse and human cancer cells","volume":"76","author":"Moreno","year":"2013","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2019.05.027_bib159","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1016\/j.bmc.2006.06.026","article-title":"Structure\u2013activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter P-glycoprotein","volume":"14","author":"Raad","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib160","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1055\/s-2006-931574","article-title":"Conferone from Ferula schtschurowskiana enhances Vinblastine cytotoxicity in MDCK-MDR1 Cells by competitively inhibiting P-glycoprotein transport","volume":"72","author":"Barthomeuf","year":"2006","journal-title":"Planta Med."},{"key":"10.1016\/j.ejmech.2019.05.027_bib161","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1055\/s-0030-1270987","article-title":"Farnesiferol A from Ferula persica and galbanic acid from Ferula szowitsiana inhibit P-glycoprotein-mediated rhodamine efflux in breast cancer cell lines","volume":"77","author":"Hanafi-Bojd","year":"2011","journal-title":"Planta Med."},{"key":"10.1016\/j.ejmech.2019.05.027_bib162","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.phymed.2009.07.009","article-title":"Antitumor activity of terpenoids against classical and atypical multidrug resistant cancer cells","volume":"17","author":"Lage","year":"2010","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2019.05.027_bib163","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.phymed.2014.06.013","article-title":"Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza","volume":"21","author":"Hu","year":"2014","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2019.05.027_bib164","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jep.2014.04.049","article-title":"Paris saponin VII from trillium tschonoskii reverses multidrug resistance of adriamycin-resistant MCF-7\/ADR cells via P-glycoprotein inhibition and apoptosis augmentation","volume":"154","author":"Li","year":"2014","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jep.2016.08.041","article-title":"A\u00a0myrsinol diterpene isolated from a traditional herbal medicine, LANGDU reverses multidrug resistance in breast cancer cells","volume":"194","author":"Wang","year":"2016","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib166","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jep.2017.03.051","article-title":"Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes","volume":"203","author":"To","year":"2017","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib167","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1021\/np070458f","article-title":"Tenacigenin B derivatives reverse P-Glycoprotein-Mediated multidrug resistance inHepG2\/dox cells","volume":"71","author":"Hu","year":"2008","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2019.05.027_bib168","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1021\/np500385b","article-title":"Polyoxypregnane Steroids from the stems of Marsdenia tenacissima","volume":"77","author":"Yao","year":"2014","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2019.05.027_bib169","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1016\/j.bmc.2016.08.022","article-title":"Triterpenoids from Momordica balsamina: reversal of ABCB1-mediated multidrug resistance","volume":"24","author":"Ramalhete","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib170","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.phrs.2009.11.010","article-title":"Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals","volume":"61","author":"Nabekura","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib171","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2009.09.040","article-title":"Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines","volume":"626","author":"El-Readi","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib172","article-title":"Anticancer drugs from marine flora: an overview","volume":"2010","author":"Sithranga Boopathy","year":"2010","journal-title":"J.\u00a0Oncol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib173","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tips.2010.02.005","article-title":"The odyssey of marine pharmaceuticals: a current pipeline perspective","volume":"31","author":"Mayer","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2019.05.027_bib174","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3390\/md10102312","article-title":"Current status on marine products with reversal effect on cancer multidrug resistance","volume":"10","author":"Abraham","year":"2012","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2019.05.027_bib175","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2146\/ajhp110237","article-title":"Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer","volume":"69","author":"McBride","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2019.05.027_bib176","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1158\/0008-5472.CAN-07-5725","article-title":"Aplidin, a marine microorganism\u2013derived compound with potent antimyeloma activity In\u00a0vitro and In\u00a0vivo","volume":"68","author":"Mitsiades","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2019.05.027_bib177","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.bcp.2010.08.001","article-title":"Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells","volume":"80","author":"Abraham","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib178","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1021\/np900091y","article-title":"Sipholane Triterpenoids: chemistry, reversal of ABCB1\/P-glycoprotein-mediated multidrug resistance, and pharmacophore modeling","volume":"72","author":"Jain","year":"2009","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2019.05.027_bib179","doi-asserted-by":"crossref","DOI":"10.3390\/md13042267","article-title":"Esters of the marine-derived triterpene Sipholenol A reverse P-gp mediated drug resistance","volume":"13","author":"Zhang","year":"2015","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2019.05.027_bib180","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.bcp.2013.02.005","article-title":"Parguerenes: marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells","volume":"85","author":"Huang","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib181","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.3390\/md12073818","article-title":"A\u00a0pyrrole alkaloid from an Australian marine sponge, Ianthella sp., reverses BCRP mediated drug resistance in cancer cells","volume":"12","author":"Huang","year":"2014","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2019.05.027_bib182","first-page":"21","article-title":"Marine natural products as models to circumvent multidrug resistance","author":"Long","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2019.05.027_bib183","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1021\/cb900134c","article-title":"Botryllamides: natural product inhibitors of ABCG2","volume":"4","author":"Henrich","year":"2009","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.05.027_bib184","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/cbdv.201300220","article-title":"Four ardeemin analogs from endophytic Aspergillus fumigatus SPS-02 and their reversal effects on multidrug-resistant tumor cells","volume":"11","author":"Zhang","year":"2014","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2019.05.027_bib185","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1021\/ol200904v","article-title":"Nocardioazines: a novel bridged diketopiperazine scaffold from a marine-derived bacterium inhibits P-glycoprotein","volume":"13","author":"Raju","year":"2011","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2019.05.027_bib186","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1021\/np5002253","article-title":"Cytotoxic dimeric epipolythiodiketopiperazines from the ascomycetous fungus Preussia typharum","volume":"77","author":"Du","year":"2014","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2019.05.027_bib187","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ejmech.2018.10.001","article-title":"The use of proteomic technologies to study molecular mechanisms of multidrug resistance in cancer","volume":"162","author":"Cao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.05.027_bib188","first-page":"1251","article-title":"Challenges and opportunities in drug discovery from plants","author":"Jachak","year":"2007","journal-title":"Curr. Sci."},{"key":"10.1016\/j.ejmech.2019.05.027_bib189","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.biotechadv.2015.08.001","article-title":"Discovery and resupply of pharmacologically active plant-derived natural products: a review","volume":"33","author":"Atanasov","year":"2015","journal-title":"Biotechnol. Adv."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419304374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419304374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:55:38Z","timestamp":1759326938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419304374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":189,"alternative-id":["S0223523419304374"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.05.027","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural products as multidrug resistance modulators in cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}